Nebivolol in Patients With Systolic Stage 2 Hypertension
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 433 participants.
Also called NCT01057251
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 433 participants
- Sponsor
- Registry
-
NCT01057251
-
- Other papers using this trial's data
- Nebivolol monotherapy for patients with systolic stage II hypertension: results of a randomized, placebo-controlled trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT01057251. Randomized; double masking; primary purpose treatment. Start 2010-03 (registry gives no type); primary completion 2010-12 (actual). Results posted on 2012-01-11.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Nebivolol in Patients With Systolic Stage 2 Hypertension
- Acronym
- NEB-MD-20
- Condition
- Hypertension
- Intervention (Drug)
- Nebivolol
- Intervention (Drug)
- Placebo
- Lead sponsor
- Forest Laboratories
Record details
- Record id
cardio:ct-nct01057251- Content hash
a0bf0792228a749b1f77c77352104d0509b45e6704b943db23250be8f618cb93